Research Topics
Genomes and Genes | Peter CampochiaroSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Ocular neovascularizationPeter A Campochiaro
Departments of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine, Maumenee 719, 600 N Wolfe Street, Baltimore, 21287 9277, MD, USA
J Mol Med (Berl) 91:311-21. 2013..While substantial progress has been made, the future looks even brighter for patients with retinal and choroidal vascular diseases...- Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edemaPeter A Campochiaro
Wilmer Eye Institute, Baltimore, Maryland, USA
Ophthalmology 119:2125-32. 2012..To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME)... - Anti-vascular endothelial growth factor treatment for retinal vein occlusionsPeter A Campochiaro
Departments of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Ophthalmologica 227:30-5. 2012..The role of adjunctive treatments is yet to be defined, but it is clear that VEGF antagonists provide excellent first-line treatment that has dramatically improved visual outcomes in patients with RVO... - Gene transfer for ocular neovascularization and macular edemaP A Campochiaro
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
Gene Ther 19:121-6. 2012.... 
Molecular targets for retinal vascular diseasesPeter A Campochiaro
Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
J Cell Physiol 210:575-81. 2007..This review summarizes preclinical and clinical trial results obtained with VEGF antagonists and describes evidence supporting the candidacy of other molecules currently being tested or soon to be tested for target status...
Gene transfer for neovascular age-related macular degenerationPeter A Campochiaro
Department of Ophthalmology and Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Hum Gene Ther 22:523-9. 2011..Many important questions remain, but the rationale and preliminary data are compelling. The results of two ongoing clinical trials may answer several of the questions and help direct future research...- Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412Peter A Campochiaro
Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Invest Ophthalmol Vis Sci 45:922-31. 2004..To evaluate the efficacy and safety of PKC412, an orally administered kinase inhibitor, in subjects with diabetic macular edema... - Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomesPeter A Campochiaro
The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Ophthalmology 117:2387-2394.e1-5. 2010..To determine the long-term effects of intraocular antagonism of vascular endothelial growth factor (VEGF) in patients with macular edema caused by retinal vein occlusions (RVOs)... - Gene therapy for ocular neovascularizationPeter A Campochiaro
The Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
Curr Gene Ther 7:25-33. 2007..It is likely that additional vectors and transgenes will enter clinical trials in the near future. This report discusses the rationale and experimental evidence regarding several candidate transgenes... - Ocular neovascularisation and excessive vascular permeabilityPeter A Campochiaro
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee 719, 600 N Wolfe Street, Baltimore, MD 21287 9277, USA
Expert Opin Biol Ther 4:1395-402. 2004..Gene transfer provides a useful way to influence these balances. Clinical trials are underway to test whether these mechanisms can be translated into new therapies... - Sustained ocular delivery of fluocinolone acetonide by an intravitreal insertPeter A Campochiaro
The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Ophthalmology 117:1393-9.e3. 2010..To compare Iluvien intravitreal inserts that release 0.2 or 0.5 microg/day of fluocinolone acetonide (FA) in patients with diabetic macular edema (DME)... - Seeing the light: new insights into the molecular pathogenesis of retinal diseasesPeter A Campochiaro
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
J Cell Physiol 213:348-54. 2007..Initial treatments that provide benefit from frequent intraocular injections are likely to be followed by sustained delivery of drugs and/or prolonged protein delivery by gene transfer. The eye has entered the era of molecular therapy... - Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulatorPeter A Campochiaro
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Mol Ther 16:791-9. 2008.... - Topical mecamylamine for diabetic macular edemaPeter A Campochiaro
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Am J Ophthalmol 149:839-51.e1. 2010..The safety and bioactivity of topical mecamylamine, an antagonist of nACh receptors, was tested in patients with diabetic macular edema... - Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disordersP A Campochiaro
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, MD 21287 9277, USA
Gene Ther 13:559-62. 2006..Based upon this early experience in vivo and in vitro, it appears that siRNAs may be valuable to help define the pathogenesis and develop new treatments for several ocular diseases... - Ocular versus extraocular neovascularization: mirror images or vague resemblancesPeter A Campochiaro
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA
Invest Ophthalmol Vis Sci 47:462-74. 2006 - Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trialPeter A Campochiaro
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Hum Gene Ther 17:167-76. 2006..11 in patients with neovascular AMD should be performed... - Monitoring ocular drug therapy by analysis of aqueous samplesPeter A Campochiaro
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Ophthalmology 116:2158-64. 2009..To assess the value of sampling aqueous humor for measurement of potential molecular targets and for pharmacokinetic analysis... - Targeted pharmacotherapy of retinal diseases with ranibizumabPeter A Campochiaro
The Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Drugs Today (Barc) 43:529-37. 2007.... - Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edemaPeter A Campochiaro
The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Ophthalmology 118:626-635.e2. 2011..To assess the efficacy and safety of intravitreal inserts releasing 0.2 μg/day (low dose) or 0.5 μg/day (high dose) fluocinolone acetonide (FA) in patients with diabetic macular edema (DME)... - Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III studyPeter A Campochiaro
Departments of Ophthalmology and Neuroscience, The Johns Hopkins School of Medicine, Baltimore, MD 21287 9277, USA
Ophthalmology 118:2041-9. 2011..Assess the 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO)... - Gene therapy for retinal and choroidal diseasesPeter A Campochiaro
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
Expert Opin Biol Ther 2:537-44. 2002.... - Retinal and choroidal neovascularizationP A Campochiaro
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
J Cell Physiol 184:301-10. 2000..This review summarizes recent progress in the field of ocular neovascularization and the prospects that it provides for the development of new treatments... - Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III studyPeter A Campochiaro
The Wilmer Eye Institute, Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Ophthalmology 117:1102-1112.e1. 2010..To assess efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema following branch retinal vein occlusion (BRVO)... - The pathogenesis of choroidal neovascularization in patients with age-related macular degenerationP A Campochiaro
The Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
Mol Vis 5:34. 1999..Identification of alterations in gene expression will provide targets for rational design of drug treatment... - Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factorKeisuke Mori
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA
Invest Ophthalmol Vis Sci 43:2428-34. 2002.... - Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) studyQuan Dong Nguyen
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Ophthalmology 116:2175-81.e1. 2009..To compare ranibizumab with focal/grid laser or a combination of both in diabetic macular edema (DME)... - AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularizationKeisuke Mori
Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA
Invest Ophthalmol Vis Sci 43:1994-2000. 2002..CONCLUSIONS: These data suggest that intraocular expression of PEDF or other antiangiogenic proteins with AAV vectors may provide a new treatment approach for ocular neovascularization... - Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growthElia J Duh
Department of Ophthalmology, Johns Hopkins University School of Medicine, Maumenee 809, 600 N. Wolfe Street, Baltimore, MD 21287, USA
Invest Ophthalmol Vis Sci 43:821-9. 2002..These findings suggest that localized administration of PEDF may be an effective approach for the treatment of ischemia-induced retinal neovascular disorders... - Trans-scleral delivery of antiangiogenic proteinsAnna M Demetriades
Department of Ophthalmology, The Johns Hopkins University, School of Medicine, Baltimore, MD, USA
J Ocul Pharmacol Ther 24:70-9. 2008..In this study, we investigated the penetration of various proteins into the mouse eye after a periocular injection of the protein or an adenoviral vector (Ad) expressing the protein... - Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathiesKeisuke Mori
Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Maumenee 719, 600 N. Wolfe Street, Baltimore, MD 21287-9277, USA
Invest Ophthalmol Vis Sci 43:1610-5. 2002..Intravitreous injection of adenoviral vectors containing appropriate expression constructs may provide a good strategy for acute treatment of proliferative retinopathies, such as diabetic retinopathy and proliferative vitreoretinopathy... - Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachmentKyoichi Takahashi
Department of Ophthalmology, The Johns Hopkins University School of Medicine, 600 N. Wolfe St, Baltimore, Maryland 21287-9277, USA
FASEB J 17:896-8. 2003..In patients with diabetic retinopathy, endostatin gene transfer may provide a way to decrease the risk of three causes of visual loss: macular edema, neovascularization, and retinal detachment... - Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathyKeisuke Mori
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Invest Ophthalmol Vis Sci 43:2001-6. 2002..This study was undertaken to determine whether higher levels of endogenously produced PDGF-A in the retinas of mice result in retinal detachment... - Agents that bind annexin A2 suppress ocular neovascularizationRaquel Lima e Silva
Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
J Cell Physiol 225:855-64. 2010.... - Trans-scleral delivery of polyamine analogs for ocular neovascularizationRaquel Lima e Silva
The Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Maumenee 719, 600 N. Wolfe Street, Baltimore, MD 21287-9277, USA
Exp Eye Res 83:1260-7. 2006.... - Vascular endothelial growth factor is a critical stimulus for diabetic macular edemaQuan Dong Nguyen
The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA
Am J Ophthalmol 142:961-9. 2006..A randomized, controlled, double-masked trial is needed to test whether intraocular injections of ranibizumab provide long-term benefit to patients with DME... - The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathiesYoshitsugu Saishin
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Invest Ophthalmol Vis Sci 44:3656-62. 2003..PKC412 should be considered for treatment of vascular and nonvascular proliferative retinopathies in humans... - Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damageGodwin Okoye
Department of Ophthalmology, Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
J Neurosci 23:4164-72. 2003..Double transgenic mice with inducible expression of survival factors provide valuable tools for selection of survival factor candidates for gene therapy... - Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine modelYoshitsugu Saishin
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA
Invest Ophthalmol Vis Sci 44:4989-93. 2003..Levels were lower but still substantial in all three compartments 20 days after periocular injection of 25% microspheres. CONCLUSIONS: Sustained local delivery of PKC412 provides a promising approach for treatment of CNV... - VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrierYoshitsugu Saishin
The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, Maryland, USA
J Cell Physiol 195:241-8. 2003.... - Oxidative stress promotes ocular neovascularizationAling Dong
Departments of Ophthalmology and Neuroscience, Johns Hopkins, University School of Medicine, Baltimore, Maryland, USA
J Cell Physiol 219:544-52. 2009..J. Cell. Physiol. 219: 544-552, 2009. (c) 2009 Wiley-Liss, Inc... - Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degenerationQuan Dong Nguyen
Department of Ophthalmology, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
Am J Ophthalmol 145:257-266. 2008..To investigate the safety, tolerability, and bioactivity of intravenous infusions of bevacizumab in patients with choroidal neovascularization (CNV) attributable to causes other than age-related macular degeneration... - Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularizationShu Kachi
Department of Ophthalmology and Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Hum Gene Ther 20:31-9. 2009..These data support proceeding toward clinical studies with EIAV-based gene therapy for choroidal NV, using the VMD2 promoter to selectively drive expression of a combination of endostatin and angiostatin in RPE cells... - Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrierPeter Gehlbach
The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287-9277, USA
Hum Gene Ther 14:129-41. 2003..These data suggest that periocular gene transfer of sFlt-1 should be considered for treatment of choroidal neovascularization and diabetic macular edema... - Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanibKyoichi Takahashi
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Arch Ophthalmol 127:494-9. 2009..To investigate pazopanib hydrochloride, a multitargeted kinase inhibitor, for treatment of choroidal neovascularization (CNV)... - Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factorKatsuaki Miki
Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287 9277, USA
Ophthalmology 116:1748-54. 2009.... - Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathiesHideo Akiyama
Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA
J Cell Physiol 207:407-12. 2006.... - Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) studyQuan Dong Nguyen
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Ophthalmology 117:2146-51. 2010..To determine the long-term effects of ranibizumab (RBZ) in patients with diabetic macular edema (DME)... - Gene transfer of an engineered zinc finger protein enhances the anti-angiogenic defense systemKatsutoshi Yokoi
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Mol Ther 15:1917-23. 2007..These data suggest that ZFP TF-driven enhancement of the endogenous anti-angiogenic defense system may provide a new approach for prophylaxis and treatment of neovascular diseases of the eye... - The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularizationRaquel Lima e Silva
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 9277, USA
FASEB J 21:3219-30. 2007..They provide new targets for therapeutic intervention that may help to bolster and supplement effects obtained with VEGF antagonists... - Mecamylamine suppresses Basal and nicotine-stimulated choroidal neovascularizationKatsuji Kiuchi
Department of Ophthalmology, The Johns Hopkins University of Medicine, Baltimore, MD 21287 9277, USA
Invest Ophthalmol Vis Sci 49:1705-11. 2008..By stimulating nAChR, nicotine promotes tumor angiogenesis as well as atherosclerotic plaque neovascularization. In this study, the authors investigated the role of nAChR in the pathogenesis of choroidal neovascularization (CNV)... - Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eyeYoshitsugu Saishin
The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Hum Gene Ther 16:473-8. 2005..These data suggest that periocular gene transfer may be feasible for treatment of human choroidal diseases... - Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachmentKyoko Ohno-Matsui
Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287 9277, USA
Am J Pathol 160:711-9. 2002..Mice with inducible expression of VEGF in the retina provide a valuable new model of ocular neovascularization... - A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degenerationQuan Dong Nguyen
Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland 21287 9277, USA
Ophthalmology 116:2141-8.e1. 2009.... - Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitiveYuji Oshima
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
FASEB J 19:963-5. 2005.... - Topical nepafenac inhibits ocular neovascularizationKyoichi Takahashi
Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287-9277, USA
Invest Ophthalmol Vis Sci 44:409-15. 2003..Because of the many advantages of the topical route of delivery, this is a possible topic for exploration... - Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularizationTsunehiko Yoshida
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
FASEB J 24:1759-67. 2010..It may also be useful for treatment of neovascular diseases in other tissues... - Blockade of nitric-oxide synthase reduces choroidal neovascularizationAkira Ando
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA
Mol Pharmacol 62:539-44. 2002..Selective inhibitors of eNOS may be needed for treatment of retinal neovascularization... - Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cellsAkiko Miki
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
J Cell Physiol 224:262-72. 2010.... - Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularizationJikui Shen
The Department of Ophthalmology, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, Maryland 21287 9277, USA
Mol Med 10:12-8. 2004..These data suggest that Npn2 facilitates VEGF-induced retinal NV and may constitute a useful target for therapeutic intervention in ocular diseases complicated by NV... - Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosisRaquel Lima e Silva
The Department of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, Maryland 21287-9277, USA
J Cell Physiol 208:161-6. 2006.... - A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degenerationQuan Dong Nguyen
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland MD 21287-9277, USA
Ophthalmology 113:1522.e1-1522.e14. 2006..0 mg/kg. This dose resulted in elimination of about 60% of excess retinal thickness after either single or multiple administrations. Alternative routes of delivery to increase the therapeutic window are being explored... - Suppression and regression of choroidal neovascularization by polyamine analoguesRaquel Lima e Silva
Department of Ophthalmology, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287-9277, USA
Invest Ophthalmol Vis Sci 46:3323-30. 2005..2 mg CGC-11144 for 2 weeks, but a single intravitreous injection compromised retinal structure and function. CONCLUSIONS: Periocular delivery of the polyamine analogues may be a useful approach for the treatment of CNV... - Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factorYuji Oshima
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
J Cell Physiol 199:412-7. 2004..The retinal neovascularization originated from both the superficial and deep capillary beds. These data suggest that Ang2 promotes sensitivity to the angiogenic effects of VEGF in retinal vessels... - Supplemental oxygen improves diabetic macular edema: a pilot studyQuan Dong Nguyen
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA
Invest Ophthalmol Vis Sci 45:617-24. 2004..CONCLUSIONS: Supplemental inspired oxygen may decrease macular thickness due to DME, suggesting that retinal hypoxia is involved in the development and maintenance of DME... - Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1Brian D Kelly
Program in Vascular Cell Engineering, Institute for Cell Engineering, Baltimore, MD, USA
Circ Res 93:1074-81. 2003.... - Ocular gene transfer with self-complementary AAV vectorsKatsutoshi Yokoi
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Invest Ophthalmol Vis Sci 48:3324-8. 2007..In this study, the authors investigated the effects of intraocular injections of type 2 scAAV.GFP in mice... - Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrierYoshitsugu Saishin
The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Cell Physiol 195:210-9. 2003..PKC412 may be useful for treatment of post-operative and inflammatory macular edema, in which prostaglandins play a role, as well as macular edema associated with ischemic retinopathies... - Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularizationYuji Oshima
The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA
J Cell Physiol 201:393-400. 2004..These data also suggest that the effects of angiogenic proteins may vary among vascular beds, even those that are closely related, and, therefore, generalizations should be avoided... - Angiopoietin-2 plays an important role in retinal angiogenesisSean F Hackett
The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, Maryland 21287 9277, USA
J Cell Physiol 192:182-7. 2002..The data also suggest that infants with PFV should be examined for genetic modifications that would be expected to cause perturbations in Tie2 signaling... - Sustained transduction of ocular cells with a bovine immunodeficiency viral vectorKyoichi Takahashi
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Hum Gene Ther 13:1305-16. 2002..There was no evidence of inflammation or toxicity in any eyes. These data show that BIV vectors mediate rapid and sustained transduction of RPE cells, suggesting that they may be useful for ocular gene therapy targeting RPE cells... - Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularizationHiroyuki Nambu
The Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, Maryland, USA
J Cell Physiol 204:227-35. 2005..These data suggest that increased expression of Ang1 may be a good strategy for prophylaxis of retinal NV, but is unlikely to be effective as monotherapy of established NV... - A method for analysis of gene expression in isolated mouse photoreceptor and Müller cellsKarl J Wahlin
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287-9257, USA
Mol Vis 10:366-75. 2004..The expression of neurotrophic factor receptors was consistent with previous biological studies. CONCLUSIONS: These studies establish a method to compare, investigate, and analyze gene expression in individual cells of the retina... - Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularizationJikui Shen
The Departments of Ophthalmology and Neuroscience The Johns Hopkins University School of Medicine Baltimore, Maryland 21287 9277, USA
FASEB J 20:723-5. 2006..These data support the hypothesis that vasohibin acts as a negative feedback regulator of neovascularization in the retina and suggest that suppression of VEGF receptor 2 may play some role in mediating its activity... - Mouse model of post-surgical breakdown of the blood-retinal barrierHansheng Liu
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9289, USA
Curr Eye Res 28:421-6. 2004..This provides a valuable tool for investigation of the molecular pathogenesis and new treatment approaches for post-surgical breakdown of the BRB... - Studies on retinal and retinal pigment epithelial gene expressionItay Chowers
Guerrieri Center for Genetic Engineering and Molecular Ophthalmology, Wilmer Eye Institute, USA
Novartis Found Symp 255:131-45; discussion 145-6, 177-8. 2004..We will also discuss technical issues that make expression studies of the RPE particularly challenging, and share our experience in methodological approaches to overcome these challenges... - Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypesLucia Sobrin
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
Ophthalmology 119:1874-85. 2012.... - In vivo immunostaining demonstrates macrophages associate with growing and regressing vesselsJikui Shen
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9277, USA
Invest Ophthalmol Vis Sci 48:4335-41. 2007..The purpose of this study was to identify ways to improve qualitative and quantitative assessments of retinal vessels and neovascularization (NV)... - Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularizationHiroyuki Nambu
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Invest Ophthalmol Vis Sci 44:3650-5. 2003..Therefore, CA-4-P shows potential for both prevention and treatment of ocular neovascularization... - An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularizationBing Xie
Department of Ophthalmology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
FASEB J 22:2775-83. 2008..Perturbation of the loop by elimination of ADAM15 suppresses ocular neovascularization in 3 different model systems, and thus ADAM15 provides a new therapeutic target for diseases complicated by neovascularization... - RPE cells modulate subretinal neovascularization, but do not cause regression in mice with sustained expression of VEGFHisashi Ida
Department of Ophthalmology, Kansai Medical University, Moriguchi, Osaka, Japan
Invest Ophthalmol Vis Sci 44:5430-7. 2003..These data do not support the conclusion of several previously reported studies, that RPE cells cause regression of CNV... - The impact of optical coherence tomography on surgical decision making in epiretinal membrane and vitreomacular tractionDiana V Do
Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Trans Am Ophthalmol Soc 104:161-6. 2006..CONCLUSIONS: OCT is more sensitive than clinical examination in detecting ERM, VMT, and associated macular edema. OCT influenced the recommendation for surgical intervention in 42.4% of patients scheduled for surgery... - Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesisElia J Duh
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Am J Ophthalmol 137:668-74. 2004..In this study, we sought to measure the levels of PEDF and vascular endothelial growth factor (VEGF) in the vitreous of patients with and without ocular neovascular disorders... - Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularizationYuji Oshima
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee, Baltimore, Maryland 21287, USA
J Cell Physiol 199:399-411. 2004..This provides a model for anterior segment neovascularization, which unlike previous models is relatively inexpensive and is not plagued by spontaneous regression, and therefore, may be useful for identification of new treatments... - Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vesselsShinji Ueno
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Cell Physiol 217:13-22. 2008..These data indicate that constant blockade of VEGF for up to 7 months has no identifiable deleterious effects on the retina or choroid and support the use of VEGF antagonists in the treatment of retinal diseases... - Protein transport to choroid and retina following periocular injection: theoretical and experimental studyFeilim Mac Gabhann
Department of Biomedical Engineering, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 720 Rutland Ave, 613 Traylor, Baltimore, MD 21205, USA
Ann Biomed Eng 35:615-30. 2007..This is the first model of ocular drug delivery to explicitly account for transport properties of each eye layer... - TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakageStanley A Vinores
The Department of Ophthalmology, The Johns Hopkins University School of Medicine, Maumenee 825, 600 N Wolfe Street Baltimore, Maryland 21287 9289, United States
J Neuroimmunol 182:73-9. 2007..Ischemia-induced retinal neovascularization, which has previously been shown to require VEGF, does not require TNF-alpha and is unaffected by attenuation of leukostasis... - VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE familyNoriko Esumi
The Guerrieri Center for Genetic Engineering and Molecular Ophthalmology, The Wilmer Eye Institute, The Departments of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 9289, USA
J Biol Chem 282:1838-50. 2007..Taken together, we suggest that VMD2 is regulated by the MITF-TFE family through two E-boxes, with E-box 1 required for a direct interaction of MITF-TFE factors and E-box 2 for binding of the as yet unidentified factor(s)... - Optical coherence tomography findings in persistent diabetic macular edema: the vitreomacular interfaceNicola G Ghazi
Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland 21287, USA
Am J Ophthalmol 144:747-754. 2007..To assess the optical coherence tomography (OCT) characteristics of eyes with persistent clinically significant diabetic macular edema (PDME) after focal laser treatment, with emphasis on the vitreomacular interface (VMI) characteristics...
Research Grants
- FUNCTIONS OF PDGFS AND FGFS IN THE RETINA AND RPEPeter Campochiaro; Fiscal Year: 1999..The third aim is to test the hypothesis that FGF receptor function is required for photoreceptor development and for their survival. ..
- Targeting survival factors for ocular neovascularizationPeter Campochiaro; Fiscal Year: 2009....
- FUNCTION OF PDGFS AND FGFS IN THE RETINA AND RPEPeter Campochiaro; Fiscal Year: 2004..This will provide important new information that is needed for the development of new treatments for these disease processes. ..
- Molecular Signals Involved in Ocular NeovascularizationPeter Campochiaro; Fiscal Year: 2005..5) Increased expression of Ang2 in the retina causes regression of neovascularization, while coexpression of Ang2 and VEGF promotes neovascularization. ..
- Oxidative damage and cone cell death in RPPeter A Campochiaro; Fiscal Year: 2010..In addition, the results may also be applicable to AMD, the most prevalent cause of severe vision loss in Americans over the age of 60. ..
- Targeting survival factors for ocular neovascularizationPeter A Campochiaro; Fiscal Year: 2010....
- Targeting survival factors for ocular neovascularizationPeter Campochiaro; Fiscal Year: 2009....
- PATHOGENIC MECHANISMS IN PROLIFERATIVE VITREORETINOPATHYPeter Campochiaro; Fiscal Year: 1993..In this manner, we hop to gain a more detailed picture of the pathogenic mechanisms involved in PVR so that strategies to prevent and interrupt them can be designed...
- RETINAL NEOVASCULARIZATION IN DIABETIC RETINOPATHYPeter Campochiaro; Fiscal Year: 2001..These studies could provide new insights into mechanisms by which retinal neovascularization occurs and identify new targets for therapeutic intervention. ..
- Oxidative damage and cone cell death in RPPeter Campochiaro; Fiscal Year: 2009..In addition, the results may also be applicable to AMD, the most prevalent cause of severe vision loss in Americans over the age of 60. ..